<DOC>
	<DOCNO>NCT01769274</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety single dose PF-05089771 placebo treatment pain patient primary , inherited erythromelalgia .</brief_summary>
	<brief_title>Evaluation Of The Efficacy And Safety Of Single Doses Of PF-05089771 In Patients With Primary ( Inherited ) Erythromelalgia</brief_title>
	<detailed_description />
	<mesh_term>Erythromelalgia</mesh_term>
	<criteria>Male female subject age 1878 year Subject clinical sign IEM Minimum BMI 17.5kg/m2 total body weight &gt; 50kg Other severe pain condition , e.g . rheumatologic , may impair subject 's selfassessment pain due IEM . Evidence clinically significant hypertension , clinically significant hematological , dermatological , renal , endocrine ( except diabetes mellitus ) , pulmonary , gastrointestinal , cardiovascular , hepatic , neurological ( IEM ) , allergic disease ( include drug allergy exclude untreated asymptomatic seasonal allergy ) . Subjects severe obesity .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>